BioRestorative Therapies, Inc. BRTX 深 滬
已收盤 08-07 16:00:00 美东时间
0.204
-0.004
-2.11%
華盛通- 最 高0.22
- 今 開0.2197
- 成交量 32.00万股
- 最 低 0.2036
- 昨 收 0.2084
- 總市值 5197.54668
- 52周最高 1.89
- 市盈率 靜 --
- 換手率 1256.12%
- 52周最低 0.1593
- 委 比 -60.00%
- 總股本 2.55万
- 歷史最高 8.90
- 量 比 0.72
- 振 幅 7.87%
- 歷史最低 0.1593
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioRestorative Therapies Completes Production For Its BRTX-100 Phase 2 Clinical Study To Support Current Clinical Development To Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, markin...
06-25 20:17
BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that the
05-26 23:03
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) shares rose 20.8% to $2.38 during Tuesday...
05-20 05:06
BioRestorative Therapies Reports 52% Of Phase 2 Patients Achieve At Least 50% Pain And Function Improvement At 52 Weeks With No Dose-Limiting Toxicity In ISCT 2026 Update
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety
05-08 00:09
BioRestorative Therapies To Reveal New Data At ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease And Its BioCosmeceutical Platform
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces that it
04-30 22:39
BioRestorative Announces Blinded Data From Phase 2 Clinical Trial Evaluating Hypoxic-Cultured Mesenchymal Stem Cells For Treatment Of Chronic Lumbar Disc Disease; Data Shows 50% Or More Of Patients Reporting >50% Improvement In Key Pain And Function Scales
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded
03-30 20:05
BioRestorative Therapies Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $19.600K Miss $520.000K Estimate
BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 4.92 percent. This is a 60 percent decrease over losses of $(0.20) per share
03-27 05:49
BioRestorative Therapies To Present Data On ~45 Participants From Its Phase 2 Clinical Study Of Hypoxic-cultured Mesenchymal Stem Cells To Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that new
03-19 20:09
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
03-10 16:42
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy
BioRestorative Therapies在2026年第一季度取得多项重要进展，包括完成其领先的临床项目BRTX-100的II期试验患者招募，获得积极的FDA Type B会议结果以及500万美元的公开募股。这些进展强化了其商业运营的发展势头。
03-04 13:00
